2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-NP0228
    Human thrombospondin 98%
    Human thrombospondin is one of a class of adhesive glycoproteins that mediate cell-to-cell and cell-to-matrix interactions. Human thrombospondin has multiple calcium-binding sites.
    Human thrombospondin
  • HY-NP0231
    Human haptoglobin, mixed type 98%
    Human haptoglobin, mixed type is a human haptoglobin with three main phenotypes: Hp 1-1, Hp 2-1, and Hp 2-2.
    Human haptoglobin, mixed type
  • HY-P0003A
    Nesiritide acetate 1684439-46-0 98%
    Nesiritide (Brain Natriuretic Peptide-32 human) acetate is a recombinant human B-type natriuretic peptide. Nesiritide acetate is a NPRs agonist, with Kd values of 7.3 and 13 pM for NPR-A and NPR-C, respectively. Nesiritide acetate regulates V1/2 activation/inactivation of the L-type calcium channel. Nesiritide acetate shows vasodilatory, diuretic, and natriuretic activities. Nesiritide acetate is used in cardiovascular diseases such as heart failure and vascular remodeling after arterial injury.
    Nesiritide acetate
  • HY-P0036B
    Octreotide pamoate 135467-16-2 98%
    Octreotide (SMS 201-995) pamoate is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide pamoate can bind to the somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide pamoate increases Gi activity and reduces intracellular cAMP production. Octreotide pamoate has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly.
    Octreotide pamoate
  • HY-P0205A
    Saralasin acetate hydrate 39698-78-7 98%
    Saralasin ([Sar1,Ala8] Angiotensin II) acetate hydrate is an octapeptide analog of angiotensin II. Saralasin acetate hydrate is a competitive angiotensin II receptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin acetate hydrate can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension.
    Saralasin acetate hydrate
  • HY-P0206B
    Bradykinin triacetate 5979-11-3 98%
    Bradykinin triacetate is an effective endothelium-dependent vasodilator that can lower blood pressure. Bradykinin triacetate can induce contraction of bronchial and intestinal non-vascular smooth muscle, increase vascular permeability, and participate in the mechanism of pain.
    Bradykinin triacetate
  • HY-P0206S
    RPPGFSPF-(Arg-13C6,15N) TFA 98%
    RPPGFSPF-(Arg-13C6,15N) TFA is the 13C- and 15N-labeled RPPGFSPF.
    RPPGFSPF-(Arg-13C6,15N) TFA
  • HY-P0306A
    Fibronectin Adhesion-promoting Peptide TFA 98%
    Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates. Fibronectin Adhesion-promoting Peptide directly promotes the adhesion, spreading, and migration of endothelial cells by reacting with heparin binding domains of cells.
    Fibronectin Adhesion-promoting Peptide TFA
  • HY-P0322A
    GRGDSPK TFA 98%
    GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption.
    GRGDSPK TFA
  • HY-P10005
    D-Val-Gly-Arg-pNA 98%
    D-Val-Gly-Arg-pNA is a chromogenic substrate of TPA (tissue plasminogen activator). D-Val-Gly-Arg-pNA can be used to detect the amidolytic activity of TPA I and TPA II.
    D-Val-Gly-Arg-pNA
  • HY-P10014
    Bibapcitide 153507-46-1 98%
    Bibapcitide, a 26 amino acid, inhibits thrombosis.
    Bibapcitide
  • HY-P10092
    SP6 98%
    SP6 exertes an antihypertensive effect through vascular NO regulation.
    SP6
  • HY-P10135
    RES-701-1 151308-34-8 98%
    RES-701-1 is a cyclic peptide composed of 16 common L-amino acids, acting as a specific antagonist for the ETB receptor. RES-701-1 can inhibit the binding of 125I-ET-1 (125I-labeled Endothelin (ET)-1) to the ETB receptor, with an IC50 value of 10 nM.
    RES-701-1
  • HY-P10151
    PD 156252 175592-65-1 98%
    PD 156252 is a hexapeptide that is a highly potent endothelin (ET) antagonist. PD 156252 has enhanced binding affinity for rabbit ETA and rat ETB receptor subtypes with IC50 values of 1.0 and 40 nM, respectively.
    PD 156252
  • HY-P1016B
    BQ-3020 ammonium 99.18%
    BQ-3020 ammonium is a selective endothelin receptor (ETB receptor) agonist. BQ-3020 ammonium inhibits [125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 ammonium elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 ammonium makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research. .
    BQ-3020 ammonium
  • HY-P10186
    Myristoylated ARF6 (2-13), scrambled 98%
    Myristoylated ARF6 (2-13), scrambled is a peptide , and is composed of amino acids 2–13 of ARF6 (MyrARF6 2–13).
    Myristoylated ARF6 (2-13), scrambled
  • HY-P10188
    apoB (4372-4392) 255822-48-1 98%
    apoB (4372-4392) is a potent lipoprotein(a) assembly inhibitor, with an IC50 of 40 μM. apoB (4372-4392) can noncovalently bind to apolipoprotein(a) with high affinity.
    apoB (4372-4392)
  • HY-P1019A
    [Ala1,​3,​11,​15]​-​Endothelin (53-63) (TFA) 98%
    [Ala1,3,11,15]-Endothelin (53-63) (TFA) is an ETB agonist. [Ala1,3,11,15]-Endothelin (53-63) (TFA) has selectivity for ETB with IC50 values range from 0.33 nM to 0.61 nM. [Ala1,3,11,15]-Endothelin (53-63) (TFA) can be used for the research of vasoconstriction.
    [Ala1,​3,​11,​15]​-​Endothelin (53-63) (TFA)
  • HY-P10258
    KRES peptide 867376-23-6 98%
    KRES peptide is an apolipoprotein with 4 amino acid residues. KRES peptide interacts with lipids, reduces lipoprotein lipid hydroperoxides (LOOH), activates antioxidant enzymes associated with high-density lipoprotein. KRES peptide exhibits anti-inflammatory and anti-atherogenic properties. KRES peptide is orally active.
    KRES peptide
  • HY-P10268
    Neuropeptide K (human, porcine, rat) 96827-05-3 98%
    Neuropeptide K, human, porcine, rat exhibits bioactivity in gallbladder contraction, protein extravasation, hypotension and brcnchial smooth muscle spasm. Neuropeptide K, human, porcine, rat is concentrated in brain and acts as tachykinin neuromessenger.
    Neuropeptide K (human, porcine, rat)
Cat. No. Product Name / Synonyms Application Reactivity